Bausch + Lomb (NYSE:BLCO) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Key Points

• JPMorgan raised Bausch + Lomb’s price target to $22 from $16 while maintaining a Neutral rating, implying roughly 8% upside from the reported $20.38 share price.
• Analyst sentiment remains mixed: the stock has an overall consensus rating of Hold, with an average price target of $20.62, although UBS and HC Wainwright issued Buy ratings and Barclays upgraded the stock to Strong Buy.
• Quarterly results exceeded expectations, with EPS of $0.34 versus the $0.21 consensus and revenue of $1.38 billion, up 7.3% year over year; however, the company still reported a negative net margin.

Bausch + Lomb (NYSE:BLCO - Get Free Report) had its price objective raised by JPMorgan Chase & Co. from $16.00 to $22.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has a "neutral" rating on the stock. JPMorgan Chase & Co.'s price objective points to a potential upside of 7.97% from the company's current price.

BLCO has been the topic of a number of other reports. Wells Fargo & Company increased their price objective on Bausch + Lomb from $18.00 to $19.00 and gave the company an "equal weight" rating in a research report on Thursday. UBS Group initiated coverage on Bausch + Lomb in a report on Thursday, July 30th. They set a "buy" rating and a $21.00 price objective for the company. Weiss Ratings upgraded shares of Bausch + Lomb from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 21st. Barclays upgraded shares of Bausch + Lomb to a "strong-buy" rating in a research report on Wednesday, October 7th. Finally, HC Wainwright reissued a "buy" rating and set a $21.00 price target on shares of Bausch + Lomb in a research note on Friday, August 28th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $20.62.

Bausch + Lomb Stock Performance

Shares of NYSE BLCO traded down $0.02 during trading hours on Thursday, reaching $20.38. The stock had a trading volume of 3,425,082 shares, compared to its average volume of 465,881. The business's fifty day moving average is $17.24 and its two-hundred day moving average is $16.66. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.55 and a quick ratio of 1.02. The company has a market cap of $7.28 billion, a price-to-earnings ratio of -42.45, a PEG ratio of 0.55 and a beta of 0.56. Bausch + Lomb has a twelve month low of $14.44 and a twelve month high of $21.36.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its earnings results on Wednesday, October 28th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.21 by $0.13. The business had revenue of $1.38 billion during the quarter, compared to analysts' expectations of $1.37 billion. Bausch + Lomb had a positive return on equity of 4.14% and a negative net margin of 3.21%. Bausch + Lomb's quarterly revenue was up 7.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.18 EPS. As a group, research analysts expect that Bausch + Lomb will post 0.81 EPS for the current year.

Insider Activity at Bausch + Lomb

In other Bausch + Lomb news, CAO Frederick Munsch sold 52,900 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $16.78, for a total value of $887,662.00. Following the completion of the sale, the chief accounting officer owned 45,831 shares in the company, valued at $769,044.18. This trade represents a 53.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Eschenbach Andrew C. Von sold 12,500 shares of the firm's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $16.50, for a total transaction of $206,250.00. Following the completion of the sale, the director owned 69,792 shares of the company's stock, valued at $1,151,568. This trade represents a 15.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 71,459 shares of company stock worth $1,194,370 in the last ninety days. Insiders own 1.45% of the company's stock.

Hedge Funds Weigh In On Bausch + Lomb

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Roxbury Financial LLC acquired a new stake in Bausch + Lomb in the third quarter valued at approximately $33,000. Royal Bank of Canada increased its holdings in shares of Bausch + Lomb by 67.1% during the first quarter. Royal Bank of Canada now owns 3,657 shares of the company's stock valued at $58,000 after acquiring an additional 1,468 shares in the last quarter. State of Wyoming raised its position in shares of Bausch + Lomb by 6.9% during the third quarter. State of Wyoming now owns 13,772 shares of the company's stock worth $234,000 after purchasing an additional 887 shares during the period. Handelsbanken Fonder AB raised its position in shares of Bausch + Lomb by 5.3% during the second quarter. Handelsbanken Fonder AB now owns 22,000 shares of the company's stock worth $364,000 after purchasing an additional 1,100 shares during the period. Finally, Squarepoint Ops LLC lifted its holdings in shares of Bausch + Lomb by 31.7% in the 2nd quarter. Squarepoint Ops LLC now owns 24,379 shares of the company's stock worth $404,000 after purchasing an additional 5,861 shares in the last quarter. 11.07% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Bausch + Lomb

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Q3 results exceeded expectations: Adjusted EPS was $0.34 versus the $0.21 consensus estimate and $0.18 a year earlier. Revenue increased approximately 7.3% year over year to about $1.38 billion, slightly ahead of the $1.37 billion estimate. Bausch + Lomb Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: 2026 outlook was raised: Bausch + Lomb now expects full-year revenue of $5.450 billion to $5.550 billion and adjusted EBITDA of $1.090 billion to $1.140 billion. Management cited continued momentum from its Vision ’27 strategy and strong growth across its eye-care businesses. Bausch + Lomb Raises 2026 Guidance
• Positive Sentiment: RBC became more bullish: RBC raised its price target to $23 from $21 while maintaining an Outperform rating, indicating greater confidence in the company’s earnings momentum and longer-term growth prospects. RBC Raises Price Target
• Neutral Sentiment: Analyst views remain mixed: Deutsche Bank raised its target to $20 from $16 but retained a Hold rating. Wells Fargo increased its target to $19 from $18 while keeping an Equal Weight rating, suggesting limited upside at recent trading levels.
• Neutral Sentiment: The earnings improvement is encouraging, but Bausch + Lomb still reported a negative net margin, so investors may continue to focus on profitability, cash flow and execution of the company’s growth plan.

About Bausch + Lomb

Bausch + Lomb Corporation NYSE: BLCO is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.